Patient's perspective of sustained remission in rheumatoid arthritis

Irazú Contreras-Yáñez, Guillermo Guaracha-Basañez, Daniel Ruiz-Domínguez, Virginia Pascual-Ramos, Irazú Contreras-Yáñez, Guillermo Guaracha-Basañez, Daniel Ruiz-Domínguez, Virginia Pascual-Ramos

Abstract

Background: During the course of rheumatoid arthritis (RA), patients have profound negative effects on their patient-reported-outcomes (PRO); in addition, the impact of sustained remission (SR) on PROs may differ for each particular outcome. The objectives of this study were to identify SR from an inception cohort of RA patients and to examine the impact of SR in an ample spectrum of PROs.

Methods: The study was developed in a well characterized and ongoing cohort of RA patients with recent onset disease recruited from 2004 onwards. In November 2016, the cohort included 187 patients, of whom 145 had at least 30 months of follow-up, with complete rheumatic assessments at regular intervals in addition to a pain visual analogue scale (PVAS), overall disease-VAS (OVAS), health assessment questionnaire (HAQ), Short-Form 36v2 Survey (SF-36) and fatigue assessment. First SR was defined according to the DAS28 cut-offs (DAS28-SR) and ACR/EULAR 2011 Boolean definition (B-SR), if maintained for at least 12 consecutive months. The dependent t test and Mc Nemar's tests were used for comparisons between related groups. Local IRB approval was obtained.

Results: More patients achieved DAS28-SR than B-SR: 78 vs. 63, respectively. Fifty patients met both SR definitions. Follow-up to DAS28-SR was shorter than to B-SR and the duration of DAS28-SR was longer, p ≤ 0.023 for all comparisons. At SR, patients had PRO proxy to normal values; the percentage of patients with normal PRO varied from 97% (95% CI: 91-99) for HAQ to 50% (95% CI: 39-61) for absence of fatigue. In DAS28-SR patients, acute reactant phases within the normal range were detected very early (after 1.5-2.9 months). HAQ, PVAS, OVAS and SF-36 were scored within the normal range after 6-7 months. The absence of fatigue was detected at 8.7 months of follow-up, which was similar to DAS28-SR. In the 63 patients with B-SR, a similar pattern was observed. The follow-up to outcomes of the 50 patients who met both SR definitions was similar, but the absence of fatigue and physical component SF-36 normalization were achieved earlier in B-SR patients (p ≤ 0.02).

Conclusions: The impact of SR on PRO differs accordingly to each particular outcome.

Keywords: Patient-reported-outcomes; Remission; Rheumatoid arthritis.

Conflict of interest statement

Authors’ information

All authors read and approved this manuscript.

Ethics approval and consent to participate

The study was approved by the Institutional Review Board of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán with the reference number IRE-274-10/11–1. All necessary consent approval was obtained from any patients involved in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no financial interests, which could create a potential conflict of interest with regard to the work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
N° (%) of patients who achieved PRO norms. Figures depicts the number (bottom of the bars) and percentage of DAS28-SR patients (dark grey bar) and B-SR patients (light grey bar) who achieved PVAS, OVAS, HAQ and SF-36 norms, ≤ 1tender joints, absence of fatigue and all PRO norms (PRO-N)
Fig. 2
Fig. 2
Months of follow-up to achieve outcomes norms in patients with DAS28-SR and B-SR

References

    1. Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, Smolen J. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum. 2009;60:1242–1249. doi: 10.1002/art.24433.
    1. van der Heijde D. Remission by imaging in rheumatoid arthritis: should this be the ultimate goal? Ann Rheum Dis 2012;71(Supll):i89-i92. Doi:10.1136/annrheumdis-2011-200797.
    1. Makinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriated tool to assess remission in rheumatoid arthritis? Ann Rheum Dis. 2005;64:1410–1413. doi: 10.1136/ard.2005.037333.
    1. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70:404–413. doi: 10.1136/ard.2011.149765.
    1. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 1981;24:1308–1315. doi: 10.1002/art.1780241012.
    1. Felson D. Defining remission in rheumatoid arthritis. Ann Rheum Dis 2012;71(0 2): i86-i88. Doi:10.1136/annrheumdis-2011-200618.
    1. West E, Jonsson SW. Health-related quality of life in rheumatoid arthritis in northern Sweden; a comparison between patients with early RA, patients with medium-term disease and controls, using SF-36. Clin Rheumatol. 2005;24:117–22.
    1. Linde l, Sorensen J, Ostergaad M, Horslev-Petersen K, Hetland ML. Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of criteria important? J Rheumatol 2010;37:285-290.
    1. Kahn KL, Mclean CH, Wong AL, Rubenstein LZ, Liu H, Fitzpatrick DM, et al. Assessment of American College of Rheumatology Quality Criteria for rheumatoid arthritis in a pre-quality criteria patient cohort. Arthritis Rheum. 2007;57:707–715. doi: 10.1002/art.22781.
    1. Hewlett S, Carr M, Ryan S, Kirwan J, Richards P, Carr A, et al. Outcomes generated by patients with rheumatoid arthritis: how important are they? Musculoskeletal Care. 2005;3:131–142. doi: 10.1002/msc.3.
    1. Sanderson T, Kirwan J. Patient-reported outcomes of arthritis: time to focus on personal life impact measures? Editorial Arthritis Rheum. 2009;61:1–3.
    1. Hewlett S. Patients and clinicians have different perspectives on outcomes in arthritis. J Rheumatol. 2003;30:877–879.
    1. Charlson M, Szatrowsky TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251. doi: 10.1016/0895-4356(94)90129-5.
    1. Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis Care Res. 1992;5:119–129. doi: 10.1002/art.1790050303.
    1. Ware JE., Jr SF-36 health survey update. Spine. 2000;25:3130–3139. doi: 10.1097/00007632-200012150-00008.
    1. Maruish ME (Ed). User’s manual for the SF-36v2 health survey (3rd edition) 2011. Lincoln RI: Qualitimetric Incorporated.
    1. Contreras-Yánez I, Pascual-Ramos V. Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters. Arthritis Res Ther 2015;17:177. DOI 10.1186/s13075-015-0697-z.
    1. Contreras-Yánez I, Rull-Gabayet M, Pascual-Ramos V. Early disease activity suppression and younger age predict excellent outcome on recent-onset rheumatoid arthritis patients with conventional disease modifying anti-rheumatic drugs. Clin Exp Rheumatol. 2012;30:402–408.
    1. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48.
    1. Krishnan E, Sokka T, Häkkinen A, Hubert H, Hannonen P. Normative values for the health assessment questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum. 2004;50(3):953–960. doi: 10.1002/art.20048.
    1. Durán-Arenas L, Gallegos-Carrillo K, Salinas-Escudero G, Martínez-Salgado H. Hacia una base normativa mexicana en la medición de calidad de vida relacionada con la salud, mediante el Formato Corto 36. Salud Publica Mex. 2004;46:306–315. doi: 10.1590/S0036-36342004000400005.
    1. Fransen J, van Riel PLCM. DAS remission cut points. Clin Exp Rheumatol. 2006;24:S29–S32.
    1. Bird P, Nicholls D, Barrett R, Jager JD, Griffiths H, Roberts L, et al. Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study. Int J Rheum Dis. 2017;20(4):460–468. doi: 10.1111/1756-185X.13036.
    1. Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther. 2014;16:R56. doi: 10.1186/ar4491.
    1. Js S, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–637. doi: 10.1136/ard.2009.123919.
    1. Thiele K, Huscher D, Bischoff SL, Späthling-Mestekemper S, Backhaus M, Aringer M, et al. Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72:1194–1199. doi: 10.1136/annrheumdis-2012-201821.
    1. Kirkham JJ, Boers M, Tugwell P, Clarke M, Williamson PR. Outcome measures in rheumatoid arthritis randomized trials over the last 50 years. Trials. 2013;14:324. doi: 10.1186/1745-6215-14-324.
    1. Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open 2015;1:e000019.doi:10.1136/rmdopen-2014-000019.
    1. Bykerk V, Massarotti EM. The new ACR/EULAR remission criteria: a rationale for developing new criteria for remission. Rheumatology 2015;51:vi16-vi20. Doi:10.1093/rheumatology/kes281.
    1. Kuriya B, Sun Y, Boire G, Haraoui B, Hitchon C, Pope JE, et al. Canadian early arthritis cohort. Remission in early rheumatoid arthritis- a comparison of new ACR/EULAR remission criteria to established criteria. J Rheumatol. 2012;39:1155–1158. doi: 10.3899/jrheum.111341.
    1. Sakellariou G, Scire CA, Verstappen SM, Montecucco C, Carporali R. In patients with early RA the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis. 2013;72:245–249. doi: 10.1136/annrheumdis-2012-201817.
    1. Aletaha D, Ward MM, Machold KP, Nell VPK, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52:2625–2636. doi: 10.1002/art.21235.
    1. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum. 2005;54:2784–2792. doi: 10.1002/art.22052.
    1. Hillsdon MM, Brunne EJ, Guralnik JM, Marmot MG. Prospective study of physical activity and physical function and early old age. Am J Prev Med. 2005;28:245–250. doi: 10.1016/j.amepre.2004.12.008.
    1. Jakobsson U, Hallberg IT. Pain and quality of life among older people with rheumatoid arthritis and/or osteoarthritis: a literature review. J Clin Nurs. 2002;11:430–443. doi: 10.1046/j.1365-2702.2002.00624.x.
    1. Radner H, Alasti F, Smolen JS, Aletaha D. Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. Arthritis Res Ther. 2015;17:203. doi: 10.1186/s13075-015-0719-x.
    1. Hewlett S, Chalder T, Choy E, Cramp F, Davis B, Dures E, et al. Fatigue in rheumatoid arthritis: time for a conceptual model. Rheumatology (Oxford) 2011;50:1004–1006. doi: 10.1093/rheumatology/keq282.
    1. Curtis JR, Shan Y, Harrold L, Zhang J, Greenberg JD, Reed GW. Patient perspectives on achieving treat to target goals: a critical examination of patient-reported outcomes. Arthritis Care Res (Hoboken) 2013;65:1707–1712. doi: 10.1002/acr.21713.
    1. Van Hoogmoed D, Fransen J, Repping-Wuts H, Spee L, Bleijenberg G, van Riel PL. The effects of anti-TNF versus DMARDs on fatigue in rheumatoid arthritis patients. Scan J Rheumatol. 2013;42:15–19. doi: 10.3109/03009742.2012.709878.
    1. Olsen CL, Lie E, Kvien TK, Zangi HA. Predictors of fatigue in rheumatoid arthritis patients in remission or in low disease activity. Arthritis Car Res. 2016;68:1043–1048. doi: 10.1002/acr.22787.
    1. Nikolaus S, Bode C, Taal E, van de Laar MA. Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. Arthritis Car Res (Hoboken) 2013;65:1128–1146. doi: 10.1002/acr.21949.
    1. Altawil R, Saevarsdottir S, Wedren S, Alfredsson L, Klareskog L, Lampa J. Remaining pain in early rheumatoid arthritis patients treated with methotrexate. Arthritis Car Res. 2016;68:1061–1068. doi: 10.1002/acr.22790.
    1. Lane SK, Gravel JW., Jr Clinical utility of common serum rheumatologic tests. Am Fam Physician. 2002;65:1073–1080.
    1. Hewlett S, Dures E, Almeida C. Measures of Fatigue. Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for Severity, Effect, and Coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength, (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness, Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Car Res 2011;63:S263.86.
    1. Covic T, Cumming SR, Pallant JF, Manolios N, Emery P, Conaghan PG, et al. Depression and anxiety in patients with rheumatoid arthritis: prevalence rates based on a comparison of the depression, anxiety and stress scale (DASS) and the hospital anxiety and depression scale (HADS) BMC Psychiatry. 2012;12:6. doi: 10.1186/1471-244X-12-6.
    1. Berkanovic E, Hurwicz ML, Lachewnbruck CA. Concordant and discrepant views of patient’s physical functioning. Arthritis Car Res. 1995;8:94–101. doi: 10.1002/art.1790080207.
    1. Molzhan AE, Northcott HC. The social bases of discrepancies in health/illness perceptions. J Adv Nurs. 1989;14:132–140. doi: 10.1111/j.1365-2648.1989.tb00911.x.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren